|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **BASEC-Nr.** | **Atopische Dermatitis** | | **Kontaktdaten** | **Status** |
| 2018-00489 | BREEZE-AD4 / I4V-MC-JAIN | A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Safety and Efficacy of Baricitinib in Combination with Topical Corticosteroids in Adult Patients with Moderate-to-Severe Atopic Dermatitis  Who Have Experienced Failure to Cyclosporine or Are Intolerant to, or Have Contraindication to, Cyclosporine | Prof. Antonio Cozzio  [Antonio.cozzio@kssg.ch](mailto:Antonio.cozzio@kssg.ch)  Tanja Zeller  [Tanja.zeller@kssg.ch](mailto:Tanja.zeller@kssg.ch) | Kein Einschluss mehr möglich |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **BASEC-Nr.** | **Melanom** | | **Kontaktdaten** | **Status** |
| 2018-01154 | Keynote 716 / MK3475-716 | Adjuvant Therapy with Pembrolizumab versus Placebo in Resected High-risk Stage II Melanoma: A Randomized, Double-Blind Phase 3 Study | Prof. Lukas Flatz  [Lukas.flatz@kssg.ch](mailto:Lukas.flatz@kssg.ch)  Tanja Zeller  [Tanja.zeller@kssg.ch](mailto:Tanja.zeller@kssg.ch) | Kein Einschluss mehr möglich |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **BASEC-Nr.** | **Basalzellkarzinom / kutanes Plattenepithelkarzinom** | | **Kontaktdaten** | **Status** |
| 2018-01154 | DUNCAN -  PH-L19IL2TNFNMSC | A phase II study of intratumoral administration of L19IL2/L19TNF in non-melanoma skin cancer patients with presence of injectable lesions. | Prof. Lukas Flatz  [Lukas.flatz@kssg.ch](mailto:Lukas.flatz@kssg.ch)  Tanja Zeller  [Tanja.zeller@kssg.ch](mailto:Tanja.zeller@kssg.ch) | **Einschluss möglich** |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **BASEC-Nr.** | **Mycosis Fungoides (MF) / Sézary Syndrome (SS)** | | **Kontaktdaten** | **Status** |
| 2016-01795 | RESMAIN study/ 4SC-201-6-2015 | A multicentre, double blind, randomised, placebo controlled, Phase II trial to evaluate Resminostat for maintenance treatment of patients with advanced stage (Stage IIB-IVB) mycosis fungoides (MF) or Sézary Syndrome (SS) that have achieved disease control with systemic therapy | Prof. Antonio Cozzio  [Antonio.cozzio@kssg.ch](mailto:Antonio.cozzio@kssg.ch)  Tanja Zeller  [Tanja.zeller@kssg.ch](mailto:Tanja.zeller@kssg.ch) | **Einschluss möglich** |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **BASEC-Nr.** | **Psoriasis** | | **Kontaktdaten** | **Status** |
| 2017-02155 | Aprescalp /  DER-USZ-AAN-021 | A phase 4 multicenter, randomized, placebo-controlled study evaluating the effect of Apremilast on pruritus and quality of life of patients with moderate-to-severe scalp Psoriasis | Prof. Antonio Cozzio  [Antonio.cozzio@kssg.ch](mailto:Antonio.cozzio@kssg.ch)  Tanja Zeller  [Tanja.zeller@kssg.ch](mailto:Tanja.zeller@kssg.ch) | **Einschluss möglich** |
| 2018-02295 | EMBRACE / CC-10004-PSOR-020 | A Phase 4, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study Of The Impact Of Apremilast (CC-10004) On Quality Of Life, Efficacy, And Safety In Subjects With Manifestations Of Plaque Psoriasis And Impaired Quality of Life | Prof. Antonio Cozzio  [Antonio.cozzio@kssg.ch](mailto:Antonio.cozzio@kssg.ch)  Tanja Zeller  [Tanja.zeller@kssg.ch](mailto:Tanja.zeller@kssg.ch) | Kein Einschluss mehr möglich |
| 2016-00135 | Secukinumab/AIN457 / CAIN457A2310 | A randomized, double-blind, placebo- and active controlled multicentre trial to demonstrate efficacy of subcutaneous secukinumab compared to placecbo and entanercept (in a single-blind arm) after twelve weeks of treatment, and to assess the safety, tolerability, and long-term efficacy in subjects from 6 to less than 18 years of age with severe chronic plaque psoriasis | Prof. Antonio Cozzio  [Antonio.cozzio@kssg.ch](mailto:Antonio.cozzio@kssg.ch)  Tanja Zeller  [Tanja.zeller@kssg.ch](mailto:Tanja.zeller@kssg.ch) | Kein Einschluss mehr möglich |
| 2016-01618 | SERENA / CAIN457A3403 | Long-term observational, prospective study to collect in a real life setting data on the retention, efficiency of secukinumab in adult patients with moderate to severe plaque psoriasis, psoriatic arthritis or ankylosing spondylitis | Prof. Antonio Cozzio  [Antonio.cozzio@kssg.ch](mailto:Antonio.cozzio@kssg.ch)  Tanja Zeller  [Tanja.zeller@kssg.ch](mailto:Tanja.zeller@kssg.ch) | Kein Einschluss mehr möglich |
| 2016-01782 | SDNTT | **Swiss Dermatology Network for Targeted Therapies (SDNTT) Objective**  Long-Term Benefits and Safety of Systemic Psoriasis Therapy:  Swiss Registry on the Treatment of Psoriasis with Biologics and Systemic Therapeutics based on PsoBest German Registry and in operational cooperation with CVderm in Hamburg | Prof. Antonio Cozzio  [Antonio.cozzio@kssg.ch](mailto:Antonio.cozzio@kssg.ch)  Tanja Zeller  [Tanja.zeller@kssg.ch](mailto:Tanja.zeller@kssg.ch) | **Einschluss möglich** |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **BASEC-Nr.** | **Prurigo Nodularis** | | **Kontaktdaten** | **Status** |
| 2020-02530 | Olympia 2 / RD.06.SPR.203065 | A Randomized, Double-Blind, Placebo-Controlled Study to Assess the  Efficacy and Safety of Nemolizumab (CD14152) in Subjects with Prurigo Nodularis | Prof. Antonio Cozzio  [Antonio.cozzio@kssg.ch](mailto:Antonio.cozzio@kssg.ch)  Tanja Zeller  [Tanja.zeller@kssg.ch](mailto:Tanja.zeller@kssg.ch) | **Einschluss möglich** |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **BASEC-Nr.** | **Urtikaria** | | **Kontaktdaten** | **Status** |
| 2018-00542 | QGE031/ Ligelizumab / QGE031C2202 | A multicentre, randomized, double-blind, placebo-controlled phase 2b dose-finding study to investigate the efficacy and safety of ligelizumab (QGE031) in adolescent patients with Chronic Spontaneous Urticaria (CSU) | Prof. Antonio Cozzio  [Antonio.cozzio@kssg.ch](mailto:Antonio.cozzio@kssg.ch)  Tanja Zeller  [Tanja.zeller@kssg.ch](mailto:Tanja.zeller@kssg.ch) | Kein Einschluss mehr möglich |

Alle Informationen zur Klinischen Forschung der Klinik für Dermatologie, Venerologie und Allergologie finden Sie unter: <https://www.kssg.ch/dermatologie/klinische-forschung>